Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Dasatinib × Clear all

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT04284202 2020-02-25

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00459342 2019-03-05

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00444015 2017-02-23

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00826449 2016-06-28

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

53 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00570401 2016-01-22

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Phase 2 Completed

22 enrolled 6 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00779389 2016-01-13

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Phase 1 Completed

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00564876 2015-02-23

TOP0706

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung